CN1122520C - Osteanaphysis capsule for treating femoral head necrosis - Google Patents

Osteanaphysis capsule for treating femoral head necrosis Download PDF

Info

Publication number
CN1122520C
CN1122520C CN00121383A CN00121383A CN1122520C CN 1122520 C CN1122520 C CN 1122520C CN 00121383 A CN00121383 A CN 00121383A CN 00121383 A CN00121383 A CN 00121383A CN 1122520 C CN1122520 C CN 1122520C
Authority
CN
China
Prior art keywords
portions
radix
parts
capsule
rhizoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN00121383A
Other languages
Chinese (zh)
Other versions
CN1335148A (en
Inventor
郭德荣
郭豪
张惠香
郭立宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN00121383A priority Critical patent/CN1122520C/en
Publication of CN1335148A publication Critical patent/CN1335148A/en
Application granted granted Critical
Publication of CN1122520C publication Critical patent/CN1122520C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a traditional Chinese medicine preparation for treating femoral head necrosis, particularly to a capsule for regenerating bones. The capsule is prepared by mixing raw materials in the following mixture proportions (proportions by weight): 4 to 6 portions of astragalus roots, 0.8 to 1.2 portions of Chinese yam, 1.6 to 2.4 portions of notoginseng, 0.8 to 1.2 portions of parasites, 0.8 to 1.2 portions of radix dipsaci from Sichuan of China, 1.6 to 2.4 portions of cyathula roots, 0.8 to 1.2 portions of earthworms, 0.8 to 1.2 portions of white peony roots, 2.5 to 3.5 portions of Chinese angelica roots, 0.8 to 1.2 portions of cortex moutan, 1.2 to 1.8 portions of safflowers, 0.8 to 1.2 portions of Tougu grass, 0.4 to 0.6 portion of pawpaws, 0.8 to 1.2 portions of eupolyphaga, 0.4 to 0.6 portion of native copper, 1.6 to 2.4 portions of water plantain, 2.5 to 3.5 portions of rhizoma corydalis, 1.2 to 1.8 portions of dahurian angelica and 0.25 to 0.35 portion of nux vomica.

Description

The capsule that is used for the treatment of femur head necrosis
Technical field
The present invention relates to a kind of oral medicinal herb medicine that is used for the treatment of femur head necrosis, belong to field of traditional Chinese.
Background technology
Femur head necrosis is a kind of difficult osteopathia, belongs to the category of the traditional Chinese medical science " osteomyelitis ", and disability rate is higher.Its pathogenic factor is more, and it is several to mainly contain traumatic, medicine, ethanol, infection etc.No matter be which kind of reason, cause capital disturbance of blood circulation the most at last, bone destruction and necrosis.Capital Therapeutic Method is varied, and commonly used have a Drug therapy, operative treatment, and massage therapy, traction treatment etc., but curative effect is all very dissatisfied.
Summary of the invention
The object of the present invention is to provide a kind of capsule that is used for the treatment of femur head necrosis.
In order to achieve the above object, technical program of the present invention lies in adopting a kind of capsule that is used for the treatment of femur head necrosis, it is made up of the component of following weight proportion:
The parasitic 0.8-1.2 part of Radix Astragali 4-6 part Rhizoma Dioscoreae 0.8-1.2 part Radix Notoginseng 1.6-2.4 part
Radix Dipsaci 0.8-1.2 part Radix Cyathulae 1.6-2.4 part Pheretima 0.8-1.2 part Radix Paeoniae Alba 0.8-1.2 part
Radix Angelicae Sinensis 2.5-3.5 part Cortex Moutan 0.8-1.2 part Flos Carthami 1.2-1.8 part Herba speranskiae tuberculatae 0.8-1.2 part
Fructus Chaenomelis 0.4-0.6 part eupolyphaga 0.8-1.2 part Pyritum 0.4-0.6 part Rhizoma Alismatis 1.6-2.4 part
Rhizoma Corydalis 2.5-3.5 part Radix Angelicae Dahuricae 1.2-1.8 part Semen Strychni 0.25-0.35 part.
It is made up of the component of following weight proportion:
1 part of 2 parts of parasitism of 1 portion of Radix Notoginseng of 5 portions of Rhizoma Dioscoreaes of the Radix Astragali
1 part of 1 portion of Radix Paeoniae Alba of 2 parts of Pheretimas of 1 portion of Radix Cyathulae of Radix Dipsaci
1 part of 1.5 parts of Herba speranskiae tuberculatae of 1 part of Flos Carthami of 3 parts of Cortex Moutans of Radix Angelicae Sinensis
2 parts of 0.5 portion of Rhizoma Alismatis of 1 part of Pyritum of 0.5 part of eupolyphaga of Fructus Chaenomelis
0.3 part of 1.5 parts of Semen Strychni of 3 parts of Radixs Angelicae Dahuricae of Rhizoma Corydalis.
The capsular preparation method of the present invention is: good each the flavor Chinese medicine of screening is in the desired amount put together, is broken into the fine flour shape with pulverizer, puts into the disinfection cabinet sterilization then, reinstall Capsules, every 0.2g, usage and consumption: each 0.4g, three times on the one, general two months is a course of treatment.
Medicine of the present invention reach " blood circulation promoting and blood stasis dispelling, kidney governing bones " theory according to " change saprophytic new " of Chinese medicine, and selected Chinese medicine is through reasonable compatibility, formulated.The elite of " change saprophytic new " theory is to rely on rotten bone, the promotion new bone growth.Femur head necrosis is strand to be organized under certain paathogenic factor effect, cause bone dissolving, subside, be out of shape, be the aseptic bone destruction that occurs under the particular environment in capsula articularis coxae.That " changes saprophytic new " is intended to, and does not destroy capital internal environment artificially.Under this guide of theory, this capsular inherent balance that focuses on adjusting bone, recover normal bio electrochemistry environment, minimizing is to capital stimulation in the joint capsule, the peace and quiet that keep ecological environment in the joint capsule, promote femur head necrosis district new bone growth in the joint capsule, quicken capital repair and reconstruction.
During this capsule raw material was formed, it is not enough that the Radix Astragali is mended all worries, beneficial vigour, strong taste; The Rhizoma Dioscoreae supplementing QI and nourishing YIN, spleen reinforcing lung kidney; The Radix Notoginseng removing stasis to stop bleeding, the analgesic therapy of invigorating blood circulation; Parasitic wind-damp dispelling, invigorating the liver and kidney, bone and muscle strengthening; The Radix Dipsaci invigorating the liver and kidney, promoting the circulation of blood arteries and veins, reuniting the fractured tendons and bones; The Radix Cyathulae blood circulation promoting and blood stasis dispelling, invigorating the liver and kidney, bone and muscle strengthening, conducting blood to flow downwards; The Pheretima blood circulation promoting and blood stasis dispelling, the diuretic heat clearing away; The Radix Paeoniae Alba yin fluid astringing that nourishes blood, easing the affected liver to relieve pain, suppressing liver-YANG; Chinese angelica blood supplementing, invigorate blood circulation, pain relieving, intestine moistening; Cortex Moutan clearing away heat and cooling blood, promoting blood circulation to remove blood stasis; The Flos Carthami blood circulation promoting and blood stasis dispelling; The Herba speranskiae tuberculatae relaxing muscles and tendons and activating QI and blood in the collateral; The Fructus Chaenomelis relaxing muscles and tendons and activating QI and blood in the collateral, removing dampness to restore normal function of the stomach; The eupolyphaga removing blood stasis, reunion of fractured tendons and bones; The Pyritum synthetism is continuous to be decreased; The pain relieving of Rhizoma Corydalis blood-activating and qi-promoting; The Rhizoma Alismatis promoting diuresis to eliminate damp pathogen expels the heat-evil; The pain relieving of Radix Angelicae Dahuricae dispeiling pathogenic wind and removing dampness; The Semen Strychni activating collaterals and eliminating stagnation, swollen clearly analgesic therapy.Above-mentioned all medicines share, and gather invigorating the spleen and replenishing QI altogether, the invigorating the liver and kidney strengthening bone and muscle, and the effects such as removing damp and stopping pain of invigorating blood circulation are given full play to " changing saprophytic new " effect, improve the femoral head local blood circulation, promote the regeneration and bone trabecular the rearranging of osteocyte, and persistent ailment must be removed.
The specific embodiment
In order to further specify effect of the present invention and essence, be illustrated below in conjunction with some clinical cases:
According to the standard of relevant scientific research case, strictness filters out femur head necrosis case 256 examples, experimental group 226 examples wherein, matched group 30 examples.
In experimental group 226 examples, male 186 examples, women 40 examples, wherein early stage 86 examples, mid-terms 100 example, late periods 40 example.In matched group 30 examples, male 21 examples, women 9 examples, wherein early stage 10 examples, mid-terms 15 example, late periods 5 example.
The therapeutic evaluation standard: according to nineteen ninety-five Dandong ischemic necrosis of femoral head of adult therapeutic evaluation method and Zhao De ischemic necrosis of femoral head of adult reparation in big 1996 with reproduce the therapeutic evaluation standard, with curative effect be divided into excellent, good, can, differ from four grades.These two Dandong standards are excellent>and 90 minutes; Good 75-89 branch; But 60-74 branch; Difference<60 minutes.Big standard of Zhao De in 1996: excellent more than 75 parts; Good more than 60 minutes; Can be more than 45 minutes; Differ from below 45 minutes.Among the present invention,, formulate following efficacy assessment standard with reference to above two standards:
Femur head necrosis four characteristics: ailing-as to subside-walk lamely-dysfunction, is foundation to the formulation of the criterion of therapeutical effect of femur head necrosis with the recovery of function and improvement, ailing alleviation, raising, short term effect and the late result satisfaction of weight capacity, and should not pursue that femur head necrosis restores later on is standard.
(1) recovery from illness standard
1, patient's subjective symptoms disappear or during climate change hip joint have or not sense of discomfort; 2, improve in the hip joint gap, and range of activity and gait are normal or be bordering on normal; 3, hip joint stagnates and locks or half stagnant lock, the patient of function limitation, and with hip joint reconstruction model, hip function in the wrong reaches about 45 degree, is bordering on the basic demand of ordinary person's hip joint; 4, X-ray film analysis, the femur head necrosis district has stopped destroying, stable disease, reconstruction again appears in the necrotic area bone structure repairs, and repairing appears in the femoral head that subsides, new bone growth, the geometric shape of carrying bone trabecula system and tension force bone trabecula system is bordering on normally.Bone trabecular intensity, density, rigidity property improve, and bearing function is bordering on normally.
(2) improvement standard
1, patient's subjective symptoms disappears or alleviates;
2, hip joint range of activity, the more preceding improvement of gait;
3, X-ray film analysis, necrotic area are stable, and the existing absorption of sequestrum, trabecular bone structure have the trend of reconstruction again, occur growth of area of new bone girder and reconstruction in the iconography.
(3) invalid standard
Patient's subjective symptoms does not have alleviation, and gait does not have improvement, and the hip joint range of activity does not have change or increases the weight of, the X-ray film analysis, and the necrotic area does not have reparation or diffusion is continued in the necrotic area.
Clinical therapeutic efficacy:
No matter be experimental group or matched group, all adopt skin traction to add the basic skills of local hot compress, all do not adopt operative therapy, different is experimental group all oral " capsule " of the present invention, the not oral any medicine of matched group.Oral " capsule ", every three months are a course of treatment, the institute example of curing the disease the shortest 4 courses of treatment, the longest 10 courses of treatment, average 7 courses of treatment.Press criterion of therapeutical effect of the present invention: in experimental group 226 examples, 116 examples of fully recovering account for 51.3%; 100 examples that take a turn for the better account for 44.3%; Invalid 10 examples account for 4.4%.Matched group 30 examples are cured 8 examples, account for 26.7%, and 16 examples that take a turn for the better account for 53.3%, and invalid 6 examples account for 20%.
The result proves: the experimental group curative effect obviously is better than matched group.
Patient utilizes this medicine to treat, and essentially no misery is taken like a shot, and curative effect is solid, and patient's cost is also lower.Key is that medicine manufacturing process and instructions of taking are simple and convenient, can improve curative effect, shorten the course of treatment, the reduction expense has improved the cure rate and the improvement rate of femur head necrosis widely, positive progradation has been played in the development of motherland's medical science, be worth in the clinical wide popularization and application of orthopaedics.
Embodiment
1 part of 2 parts of parasitism of 1 portion of Radix Notoginseng of 5 portions of Rhizoma Dioscoreaes of the Radix Astragali
1 part of 1 portion of Radix Paeoniae Alba of 2 parts of Pheretimas of 1 portion of Radix Cyathulae of Radix Dipsaci
1 part of 1.5 parts of Herba speranskiae tuberculatae of 1 part of Flos Carthami of 3 parts of Cortex Moutans of Radix Angelicae Sinensis
2 parts of 0.5 portion of Rhizoma Alismatis of 1 part of Pyritum of 0.5 part of eupolyphaga of Fructus Chaenomelis
0.3 part of 1.5 parts of Semen Strychni of 3 parts of Radixs Angelicae Dahuricae of Rhizoma Corydalis
Good each the flavor Chinese medicine of screening is in the desired amount put together, is ground into the fine flour shape with pulverizer, puts into the disinfection cabinet sterilization then, reinstalls Capsules, every 0.2g, and usage and consumption: each 0.4g, three times on the one, general two months is a course of treatment.

Claims (2)

1, a kind of capsule that is used for the treatment of femur head necrosis, it is characterized in that: it is made up of the component of following weight proportion:
The parasitic 0.8-1.2 part of Radix Astragali 4-6 part Rhizoma Dioscoreae 0.8-1.2 part Radix Notoginseng 1.6-2.4 part
Radix Dipsaci 0.8-1.2 part Radix Cyathulae 1.6-2.4 part Pheretima 0.8-1.2 part Radix Paeoniae Alba 0.8-1.2 part
Radix Angelicae Sinensis 2.5-3.5 part Cortex Moutan 0.8-1.2 part Flos Carthami 1.2-1.8 part Herba speranskiae tuberculatae 0.8-1.2 part
Fructus Chaenomelis 0.4-0.6 part eupolyphaga 0.8-1.2 part Pyritum 0.4-0.6 part Rhizoma Alismatis 1.6-2.4 part
Rhizoma Corydalis 2.5-3.5 part Radix Angelicae Dahuricae 1.2-1.8 part Semen Strychni 0.25-0.35 part.
2, capsule according to claim 1 is characterized in that: it is made up of the component of following weight proportion:
1 part of 2 parts of parasitism of 1 portion of Radix Notoginseng of 5 portions of Rhizoma Dioscoreaes of the Radix Astragali
1 part of 1 portion of Radix Paeoniae Alba of 2 parts of Pheretimas of 1 portion of Radix Cyathulae of Radix Dipsaci
1 part of 1.5 parts of Herba speranskiae tuberculatae of 1 part of Flos Carthami of 3 parts of Cortex Moutans of Radix Angelicae Sinensis
2 parts of 0.5 portion of Rhizoma Alismatis of 1 part of Pyritum of 0.5 part of eupolyphaga of Fructus Chaenomelis
0.3 part of 1.5 parts of Semen Strychni of 3 parts of Radixs Angelicae Dahuricae of Rhizoma Corydalis.
CN00121383A 2000-07-26 2000-07-26 Osteanaphysis capsule for treating femoral head necrosis Expired - Fee Related CN1122520C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN00121383A CN1122520C (en) 2000-07-26 2000-07-26 Osteanaphysis capsule for treating femoral head necrosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN00121383A CN1122520C (en) 2000-07-26 2000-07-26 Osteanaphysis capsule for treating femoral head necrosis

Publications (2)

Publication Number Publication Date
CN1335148A CN1335148A (en) 2002-02-13
CN1122520C true CN1122520C (en) 2003-10-01

Family

ID=4588766

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00121383A Expired - Fee Related CN1122520C (en) 2000-07-26 2000-07-26 Osteanaphysis capsule for treating femoral head necrosis

Country Status (1)

Country Link
CN (1) CN1122520C (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100444856C (en) * 2005-06-01 2008-12-24 周友生 Medicine for treating femur osteonecrosis and its preparation method
CN100418582C (en) * 2005-11-25 2008-09-17 上海第二医科大学附属第九人民医院 Microcapsule for promoting bone regeneration and its use
CN102973782A (en) * 2012-12-25 2013-03-20 青岛海尔软件有限公司 Traditional Chinese medicine composition used for treating femoral head necrosis

Also Published As

Publication number Publication date
CN1335148A (en) 2002-02-13

Similar Documents

Publication Publication Date Title
CN102488869B (en) Traditional Chinese medicinal external-use liniment for muscle and bone ache
CN1861187A (en) Medicated wine for treating rheumatosis and osteoarthropathy
CN1380095A (en) Ointment for curing rheumatism and osteoarthropathy
CN1278446A (en) Chinese medicinal composition for cerebrovascular disease, rheumatism and rheumatoid disease
CN1336225A (en) Cerebral thrombus treating traditional Chinese medicine
CN1069527C (en) Medicine for hyperosteogeny and wind-cold syndrome
CN1698735A (en) Medicine for treating psoriasis
CN1122520C (en) Osteanaphysis capsule for treating femoral head necrosis
CN1247233C (en) Chinese medicine for varicose vein
CN1310014A (en) Lumbago treating Chinese medicine
CN1247238C (en) Chinese medicine ointment preparation for curing hyperosteogeny, pain and numbness and its production method
CN1238018C (en) Plaster for treating pain in neck, shoulder, waist and lower extremities
CN1284580C (en) Bone Activating stasis transforming capsule
CN1141114C (en) Tendon-conditioning analgetic
CN1063650C (en) Chinese medicinal pill for curing rheumatism and rheumatoid disease and its preparation method
CN1186056C (en) medicine for treating hyperosteogeny
CN100346807C (en) Fuming-washing Chinese medicine for treating bone joint disease
CN104857441A (en) Oral preparation for treating femoral head necrosis and preparation method of oral preparation
CN1387877A (en) Tonic wine for resisting rheumatism and rhematoid diseases
CN108888736B (en) External-use bone reunion medicine and preparation method thereof
CN1113807A (en) Anti-headache Chinese proprietary medicine and its preparing method
CN101322787B (en) Specific medicinal liquor for treating rheumatoild disease
CN105560427A (en) Transdermal gate-freeing powder
CN100344317C (en) Gastrodia tuber capsule and its preparation process
CN1698801A (en) Capsule for treating hemiplegia and rheumatism

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee